The European Commission has escalated its review of the pharmaceutical sector by initiating a formal antitrust investigation into French multinational healthcare giant Sanofi. Regulators are looking into whether the company weaponized its marketing to unfairly squash its only direct competitor in the high-dosage influenza vaccine market for older adults.
According to an official statement, the investigation centers on concerns that Sanofi may have violated EU competition laws by executing a targeted communication campaign designed to discredit a rival product.The dispute involves “an enhanced flu vaccine, which is specifically designed to provide greater protection against influenza for people over 60.” In the European Union, Sanofi markets this product under the brand name Efluelda.
Sanofi’s dominant position in major European markets puts it head-to-head with its only direct rival in this specific therapeutic space: an enhanced flu vaccine called Fluad, manufactured by CSL Seqirus. Because these vaccines target highly vulnerable patient groups with specific risk factors, national immunization guidelines carry enormous financial and medical weight for both companies.
The European Commission’s primary concern is that Sanofi utilized a “misleading communication campaign to disparage Fluad by portraying it as inferior to Efluelda.” Regulators noted that this strategy appeared to intentionally counter official “national vaccination recommendations in several Member States,” specifically targeting healthcare professionals across France and Germany.Brussels has outlined a preliminary assessment highlighting three distinct tactics allegedly used in Sanofi’s messaging campaign to sway doctors and health professionals.
First, the Commission pointed to “claims suggesting that the evidentiary basis for Fluad is weaker than that for Efluelda.” European officials emphasized that these assertions directly “contradict the findings of the European Centre for Disease Control and national immunisation technical advisory groups in Germany and France.”
Second, the probe identifies “misleading and/or inaccurate representations of national vaccination recommendations” distributed to medical professionals.
Finally, the Commission highlighted specific marketing efforts within Germany that alleged “the national vaccination recommendation for Fluad remains subject to unresolved scientific objections from medical professional societies.”The European Commission believes these combined actions may represent an illegal abuse of market dominance. If the allegations are validated, Sanofi’s behavior would violate Article 102 of the Treaty on the Functioning of the European Union (TFEU), which strictly prohibits dominant market players from engaging in practices that “prevent or restrict competition within the Single Market.”
This formal announcement follows a series of unannounced inspections carried out at Sanofi’s corporate premises in September 2025. Along with opening the proceedings, the Commission issued a Preliminary Assessment detailing its specific competition concerns.
To resolve the matter without a formal binding penalty, Sanofi has the option to submit structural or behavioral remedies. Under EU antitrust frameworks, the company “may now submit commitments” to address the regulator’s concerns. If the Commission accepts these commitments, it can conclude the proceedings without a formal finding of infringement, legally binding Sanofi to its promises.
Regulators have made it clear that “the opening of a formal investigation does not prejudge its outcome,” and there is no strict legal deadline to conclude the probe. The investigation’s timeline will ultimately rest on the complexity of the medical evidence, how thoroughly Sanofi cooperates with Brussels, and the defense strategies utilized by the pharmaceutical company.
